NIFTY may trade in the range 5350-5420
Friday, July 30, 2010 6:27Mixed global cues led the JULY F&O expiry day end on a flat note. BANKING, REALITY and FMCG witnessed good buying while IT, CAPITAL GOODS and METALS saw good gains. SENSEX closed at 17992, up 34 points and Nifty at 5408, up 11 points from the previous close. CNX MIDCAP index was up 0.2% and BSE SMALLCAP index was down 0.1%. The market breadth was negative with advances at 588 against declines of 681 on the NSE. Top gainers included HINDALCO, HDFC, ICICIBANK, TATAMOTORS, HUL, IDFC and CAIRN. Top losers are listed as RCOM, BHARTIARTL, RELINFRA, JINDALSTEL, CIPLA, SUZLON, SUNPHARMA, SAIL and RPOWER.
In the next session NIFTY may trade in the range 5350-5420, breaching of level either side may decide the trend. Traders are suggested to avoid long positions below 5350. BANKING STOCKS may attract buying while METALS and HEALTH CARE HEAVYWEIGHTS may face selling.
Investors who have a horizon of 6-12 months can buy the following companies. The companies have potential to give higher returns than index over a long term.
Ashok Leyland, the flagship company of the London-based Hinduja Group has announced today that it had reached agreement with Optare plc, a leading bus manufacturer in the UK to subscribe for a 26% stake as a part of long-term strategic cooperation. The investment is estimated at about US$ 7.5 million.
Glenmark Generics Inc, the United States subsidiary of Glenmark Generics has announced that the United States Food and Drug Administration (USFDA) has granted tentative approval for Riluzole 50 mg tablets, the generic version of Rilutek tablets by Sanofi Aventis US LLC.
Sun Pharmaceutical Industries has announced that the U. S. Court of Appeals for the Federal Circuit affirmed the judgment of the U. S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U. S. Patent No. 5,464,826 (826 patent) invalid.
Disclaimer: The above mentioned ideologies are based on the research done at Fairwealth research department. Fairwealth securities (P) Ltd will not be responsible for any kind of losses incurred by any part either directly or indirectly based on our research results, though we have presented to the best of our knowledge.
